Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells

Sisi Wang, Hongyong Zhang, Michael Malfatti, Ralph W deVere White, Primo N Lara, Ken W Turteltaub, Paul Henderson, Chong-Xian Pan

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

We are developing a method to identify cellular resistance to carboplatin by using accelerator mass spectrometry to measure carboplatin-DNA adducts formed from drug microdoses (∼1/100th the therapeutic dose). Such an approach would be particularly useful if it is still valid in combination chemotherapy. We examined whether the addition of gemcitabine, another chemotherapeutic drug, could influence carboplatin-DNA adduct levels. There were no substantial differences in the levels of carboplatin-DNA adducts in cells upon exposure to the carboplatin/gemcitabine combination at various doses and schedules. These data demonstrate that microdosing is feasible for the characterization of carboplatin resistance when given in combination with gemcitabine.

Original languageEnglish (US)
Pages (from-to)1653-1655
Number of pages3
JournalChemical Research in Toxicology
Volume23
Issue number11
DOIs
StatePublished - Nov 15 2010

ASJC Scopus subject areas

  • Toxicology

Fingerprint Dive into the research topics of 'Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells'. Together they form a unique fingerprint.

  • Cite this